RENOVIST II Drug Patent Profile
✉ Email this page to a colleague
When do Renovist Ii patents expire, and what generic alternatives are available?
Renovist Ii is a drug marketed by Bracco and is included in one NDA.
The generic ingredient in RENOVIST II is diatrizoate meglumine; diatrizoate sodium. There are eleven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the diatrizoate meglumine; diatrizoate sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Renovist Ii
A generic version of RENOVIST II was approved as diatrizoate meglumine; diatrizoate sodium by ANDA REPOSITORY on June 27th, 2022.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for RENOVIST II?
- What are the global sales for RENOVIST II?
- What is Average Wholesale Price for RENOVIST II?
Summary for RENOVIST II
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 5 |
| Patent Applications: | 190 |
| DailyMed Link: | RENOVIST II at DailyMed |
Pharmacology for RENOVIST II
| Drug Class | Radiographic Contrast Agent |
| Mechanism of Action | X-Ray Contrast Activity |
US Patents and Regulatory Information for RENOVIST II
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bracco | RENOVIST II | diatrizoate meglumine; diatrizoate sodium | INJECTABLE;INJECTION | 010040-019 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
